Fate Therapeutics Inc
Închisă
SectorSănătate
1.95 3.17
Rezumat
Modificarea prețului
24h
Minim
1.8900000000000001
Maxim
2.01
Venit | 1.2M -31M |
|---|---|
Vânzări | -70K 1.3M |
EPS | -0.26 |
Marjă de profit | -2,402.848 |
Angajați | 161 |
EBITDA | 14M -28M |
Recomandări | Cumpărare |
|---|---|
Prognoză pe 12 luni | +151.58% upside |
Următoarele câștiguri | 10 aug. 2026 |
|---|
Capitalizare de piață | -19M 234M |
|---|---|
Deschiderea anterioară | -1.22 |
Închiderea anterioară | 1.95 |
Sentimentul știrilor
By Acuity
28%
72%
79 / 342 Clasament în Healthcare
Fate Therapeutics Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
